PHARMA TITANS • 2018-2026
Top 8 Big Pharma Empires by Market Cap (2018-2026): The $1.26T Surge!
Market Capitalization in USD Billions ($B)
Key takeawayEli Lilly surged 999% to $1,265B on GLP-1 dominance
Watch the video
Open on YouTube
Free download
Get the full 2018-2026 dataset
Spreadsheet-ready (Excel, Google Sheets). Developer-ready, free to reuse with attribution.
Recommended next step
Get it $0+
Automate this workflow free with Make.com
Turn spreadsheets like this into automated reports and alerts without code. Free plan available.
Pro Pack on Gumroad
Audio-Locked Faceless Avatar Media Pipeline & Credit-Saver Studio (5-in-1 Creator Suite)Affiliate link: we may earn a commission at no extra cost to you.
2018 vs 2026: what changed
2018 leader
J&J $346B
2026 leader
Eli Lilly $1,265B
Fastest growth
Eli Lilly +12.1% CAGR
| Contender | 2018 | 2026 | Multiplier | CAGR | Peak (year) | 2026 share |
|---|---|---|---|---|---|---|
| Eli Lilly | $115B | $1,265B | 11.00x | +12.10% | $1,265B (2026) | 32.5% |
| J&J | $346B | $664B | 1.92x | +3.15% | $664B (2026) | 17.1% |
| AbbVie | $138B | $524B | 3.80x | +6.56% | $524B (2026) | 13.5% |
| Roche | $209B | $397B | 1.90x | +3.10% | $397B (2026) | 10.2% |
| Merck | $198B | $370B | 1.87x | +3.02% | $370B (2026) | 9.5% |
| Novartis | $200B | $305B | 1.52x | +2.03% | $305B (2026) | 7.8% |
| Novo Nordisk | $110B | $197B | 1.79x | +2.81% | $640B (2024 Q2) | 5.1% |
| Pfizer | $253B | $171B | 0.68x | -1.85% | $331B (2021 H2) | 4.4% |
| Contender | 2018 | 2019 H1 | 2019 H2 | 2020 H1 | 2020 H2 | 2021 H1 | 2021 H2 | 2022 H1 | 2022 H2 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | $115B | $108B | $125B | $155B | $161B | $210B | $264B | $308B | $347B | $326B | $445B | $510B | $553B | $740B | $850B | $865B | $790B | $825B | $870B | $895B | $915B | $1,265B |
| J&J | $346B | $370B | $384B | $372B | $414B | $435B | $450B | $467B | $461B | $405B | $430B | $375B | $377B | $381B | $359B | $390B | $365B | $410B | $455B | $485B | $515B | $664B |
| AbbVie | $138B | $108B | $131B | $162B | $189B | $199B | $239B | $270B | $285B | $281B | $238B | $263B | $274B | $322B | $310B | $348B | $335B | $360B | $382B | $398B | $415B | $524B |
| Roche | $209B | $240B | $276B | $295B | $298B | $330B | $355B | $290B | $251B | $230B | $242B | $218B | $234B | $205B | $245B | $262B | $248B | $270B | $285B | $298B | $312B | $397B |
| Merck | $198B | $215B | $230B | $195B | $206B | $196B | $194B | $231B | $281B | $270B | $292B | $261B | $276B | $334B | $320B | $288B | $252B | $264B | $272B | $279B | $285B | $370B |
| Novartis | $200B | $218B | $224B | $204B | $213B | $205B | $198B | $192B | $196B | $198B | $210B | $212B | $218B | $206B | $225B | $234B | $215B | $228B | $239B | $247B | $255B | $305B |
| Novo Nordisk | $110B | $122B | $138B | $152B | $163B | $198B | $258B | $255B | $306B | $365B | $362B | $415B | $460B | $568B | $640B | $535B | $410B | $390B | $365B | $348B | $334B | $197B |
| Pfizer | $253B | $240B | $216B | $182B | $204B | $219B | $331B | $294B | $288B | $230B | $207B | $188B | $163B | $157B | $158B | $164B | $150B | $155B | $160B | $164B | $168B | $171B |